Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Carboplatin

Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles

DRUG

Bevacizumab

Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression

DRUG

Paclitaxel

Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles

Trial Locations (10)

Unknown

University Hospital of Heraklion, Dep of Medical Oncology, Heraklion

University General Hospital of Alexandroupolis, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

State General Hospital of Larissa, Dep of Medical Oncology, Larissa

"Diabalkaniko hospital, Thessaloniki", Thessaloniki

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

All Listed Sponsors
lead

Hellenic Oncology Research Group

OTHER